Abstract
Introduction: The prospective, noninterventional, multicenter PERSIST study evaluates effectiveness and safety of guselkumab and ustekinumab in patients with moderate-to-severe plaque psoriasis in a German real-world setting. Week (W) 52 data of 303 patients treated with guselkumab are presented.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
